For Healthcare Professionals

A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors


About the study

The purpose of this study is to evaluate the safety and tolerability of AB521 when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Disease-specific criteria for dose escalation:
  2. Participants may have any pathologically confirmed solid tumor type where no other treatment options are available.
  3. Disease-specific criteria for dose-expansion:
  4. Histologically confirmed ccRCC, must have received prior treatment in the metastatic setting (either individually or in combination) with an anti-programmed cell death protein 1 (anti-PD-1) therapy and a tyrosine kinase inhibitor (TKI), and no prior treatment with a hypoxia inducible factor (HIF)-2 alpha (α)-targeting therapy.
  5. Must have at least one measurable lesion per RECIST guidance.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1.


Key Exclusion Criteria:

  1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product.
  2. Underlying medical conditions that, in the investigator's judgment, will make the administration of investigational product hazardous (eg, interstitial lung disease, active infections requiring antibiotics, recent hospitalizations with unresolved symptoms) or obscure the interpretation of toxicity determination or AEs.
  3. History of trauma or major surgery within 28 days prior to the first dose of investigational product.
  4. For monotherapy dose expansion: prior treatment with an HIF-2α inhibitor.
  5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Clear Cell Renal Cell Carcinoma,Solid Tumors

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Jan 31, 2026

Treatment type



Arcus Biosciences, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.